Sun Pharma v. Incyte: Federal Circuit Reverses JAK Inhibitor Patent Ruling
Sun Pharmaceutical Industries challenged Incyte Corporation over US9662335B2, a patent covering JAK inhibitor compounds implicated in Incyte’s Olumiant® (baricitinib), Jakafi® (ruxolitinib), and Sun’s own CTP-543 deuruxolitinib. The Federal Circuit reversed the lower decision in 176 days, reshaping the patent landscape for this high-value drug class.
Federal Circuit overturns JAK inhibitor patent decision in Sun v. Incyte
Sun Pharmaceutical Industries, Inc. brought this appeal against Incyte Corporation and Incyte Holdings, Corp. at the Court of Appeals for the Federal Circuit, docketed as Case No. 25-1162. The dispute centres on US9662335B2, a patent directed to JAK inhibitor compounds — a mechanistic class underpinning blockbuster drugs including Incyte’s Olumiant® (baricitinib) and Jakafi® (ruxolitinib), as well as Sun’s pipeline asset CTP-543 (deuruxolitinib). The appeal was filed on 12 November 2024.
The Federal Circuit issued its order on 7 May 2025, reversing the lower court’s decision after 176 days. The single-line disposition — ‘REVERSED’ — indicates the appellate panel found reversible error in the ruling below, effectively vacating that outcome and handing Sun Pharmaceutical a favourable appellate result. The basis of termination is recorded as ‘Case Reversed,’ with no publicly disclosed settlement or consent judgment accompanying the order.
A 176-day timeline from filing to decision is notably fast for a pharmaceutical patent appeal at the Federal Circuit, suggesting the panel may have resolved a discrete legal question — potentially claim construction, eligibility, or standing — rather than conducting a full merits re-examination. The precise ground of reversal is not detailed in the available public record, meaning the downstream implications for each product’s market exclusivity remain to be determined by any remand proceedings.
Filing to Case Reversed in 176 days
176-day resolution — notably swift for a Federal Circuit pharmaceutical patent appeal
Federal Circuit reverses: what the ruling means for both parties
What ‘REVERSED’ means at the Federal Circuit
A reversal by the Federal Circuit means the appellate panel identified reversible error in the lower tribunal’s decision — whether legal, procedural, or factual — and has overturned that outcome. Unlike an affirmance, the prior decision no longer stands. Depending on the scope of the order, the case may be remanded for further proceedings consistent with the appellate ruling, or the reversal may itself resolve the dispute.
Lower decision overturnedSun Pharmaceutical wins on appeal — enforcement position strengthened
As the appellant, Sun Pharmaceutical obtained the outcome it sought: the Federal Circuit agreed that the lower decision was erroneous. This restores or advances Sun’s legal position regarding US9662335B2. For a company with CTP-543 (deuruxolitinib) in development, a favourable appellate ruling on the underlying JAK inhibitor patent can have significant implications for competitive freedom-to-operate and any future licensing or enforcement strategy.
Sun Pharma — appeal succeededIncyte faces renewed exposure on JAK inhibitor patent claims
Incyte Corporation and Incyte Holdings, Corp., as appellees, had prevailed below — a position the Federal Circuit has now overturned. With Olumiant® and Jakafi® among the products in scope, any remand or reinstatement of claims carries commercial risk for two significant revenue-generating assets. Incyte’s options at this stage are limited to seeking en banc rehearing at the Federal Circuit or petitioning the Supreme Court for certiorari.
Incyte — lower win reversedJAK inhibitor IP landscape shifts after Federal Circuit reversal
Reversals at the Federal Circuit in pharmaceutical infringement actions typically signal a recalibration of claim scope or validity standards with sector-wide effects. Companies developing JAK inhibitor therapeutics — a class spanning rheumatoid arthritis, myelofibrosis, alopecia areata, and beyond — should reassess FTO positions in light of this ruling. The outcome also raises the bar for defendants relying on the same lower-court reasoning that Incyte used successfully before this appeal.
JAK inhibitor FTO risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Sun Pharmaceutical Industries, Inc. | Company | Pharmaceutical company and appellant — holder of US9662335B2 (JAK inhibitor patent)Search in Eureka ↗ |
| Co-Plaintiff | Sun Pharmaceutical Industries, Inc. | Company | Search in Eureka ↗ |
| Defendant | Incyte Corporation | Company | Biopharmaceutical company; maker of Olumiant® (baricitinib) and Jakafi® (ruxolitinib)Search in Eureka ↗ |
| Co-Defendant | Incyte Holdings, Corp. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander N. Harris | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Blaine H. Evanson | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Charlotte Jacobsen | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine Ranney | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Josh Krevitt | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Paul E. Torchia | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibson Dunn & Crutcher, LLP | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel F. Roland | Attorney | Counsel for Incyte CorporationSearch in Eureka ↗ |
| Defendant counsel | Danielle Andrea Duszczyszyn | Attorney | Counsel for Incyte CorporationSearch in Eureka ↗ |
| Defendant counsel | J. Derek McCorquindale | Attorney | Counsel for Incyte CorporationSearch in Eureka ↗ |
| Defendant counsel | Jason Lee Romrell | Attorney | Counsel for Incyte CorporationSearch in Eureka ↗ |
| Defendant counsel | Mark J. Feldstein | Attorney | Counsel for Incyte CorporationSearch in Eureka ↗ |
| Defendant counsel | Martin David Weingarten Ph.D. | Attorney | Counsel for Incyte CorporationSearch in Eureka ↗ |
| Defendant counsel | Megan Meyers | Attorney | Counsel for Incyte CorporationSearch in Eureka ↗ |
| Defendant law firm | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | Law Firm | Representing Incyte CorporationSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: REVERSED’ — is a clean, unconditional reversal with no accompanying opinion excerpt in the public docket summary. Appellate courts reverse when they find the lower tribunal committed an error of law or applied an incorrect legal standard; the absence of an ‘affirmed-in-part’ qualifier suggests the error was not limited to a discrete sub-issue. Both parties and the market should treat the lower decision as having no precedential or preclusive effect on the claims addressed, pending any remand proceedings.
US9662335B2 — JAK inhibitor pharmaceutical compositions
US9662335B2 (application number US15/173057) is directed to JAK (Janus kinase) inhibitor compositions — a mechanistically significant class of small-molecule drugs that modulate immune and inflammatory signalling pathways. JAK inhibitors have generated multi-billion-dollar revenue streams across oncology, rheumatology, and dermatology indications. The patent’s claim scope, as contested in this litigation, encompasses compounds relevant to at least three distinct commercial and pipeline products: baricitinib, ruxolitinib, and deuruxolitinib.
The strategic importance of US9662335B2 derives from the breadth of the JAK inhibitor market and the number of approved and pipeline products potentially within its claim scope. Incyte’s Jakafi® (ruxolitinib) holds FDA approval for myelofibrosis and polycythemia vera, while Olumiant® (baricitinib) is approved for rheumatoid arthritis and alopecia areata. Sun’s CTP-543 (deuruxolitinib) targets alopecia areata directly, making claim scope determinations on this patent a live commercial question for multiple market participants simultaneously.
Should your team run an FTO against US9662335B2?
Any R&D or product team working on JAK inhibitor compounds — particularly those targeting alopecia areata, myelofibrosis, or rheumatoid arthritis indications — should treat this patent as an active FTO risk. The Federal Circuit’s reversal means prior clearance opinions that relied on the lower court’s outcome should be revisited. Companies developing selective JAK1 or JAK2 inhibitors, deuterated JAK inhibitors, or formulation variants of existing JAK inhibitor scaffolds are most directly exposed.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US9662335B2 against your compound’s structural and functional features, identify continuation and divisional risk in the same patent family, and surface prosecution history estoppel arguments relevant to the reversed claim construction. With post-reversal uncertainty at its highest, automated FTO monitoring ensures you receive alerts if remand proceedings alter the operative claim scope before your next development milestone.
Run a freedom-to-operate analysis on US9662335B2 to assess your product’s exposure
Run FTO in Eureka →Related JAK inhibitor patent appeals at the Federal Circuit
Cases involving JAK inhibitor pharmaceutical patents before the Federal Circuit, where claim construction or validity determinations have shaped commercial exclusivity for approved drugs.
What this case signals for the JAK inhibitor pharmaceutical IP landscape
The Federal Circuit’s reversal in Sun v. Incyte has direct implications for patent enforcement and product strategy across the JAK inhibitor drug class.
Reversal resets the competitive dynamic for JAK inhibitor patent enforcement
Any pharma company whose FTO analysis for a JAK inhibitor asset relied on the now-reversed lower decision should treat that analysis as stale. The Federal Circuit’s reversal suggests the lower tribunal applied an erroneous legal standard, which — depending on the ground — could affect how similar claims are construed in related proceedings.
CTP-543 deuruxolitinib development trajectory warrants close monitoring
With Sun’s CTP-543 explicitly among the products at issue, the reversal may directly affect Sun’s freedom to develop, launch, or license deuruxolitinib. Competitors and partners in the JAK inhibitor alopecia areata space should track any remand proceedings for claim scope determinations that could define the next litigation cycle.
Sun v Incyte — key questions answered
The Federal Circuit reversed the lower court’s decision in Case No. 25-1162. The court’s order states ‘ORDERED AND ADJUDGED: REVERSED,’ overturning the prior ruling in Incyte’s favour. The specific ground of reversal is not detailed in the publicly available docket summary, but the outcome restores Sun Pharmaceutical’s legal position regarding US9662335B2.
The patent at issue is US9662335B2 (application number US15/173057), directed to JAK inhibitor pharmaceutical compositions. The products implicated include Incyte’s Olumiant® (baricitinib), Incyte’s Jakafi® (ruxolitinib), and Sun Pharmaceutical’s pipeline product CTP-543 (deuruxolitinib).
The reversal means the lower court’s decision — which had favoured Incyte — no longer stands. Incyte faces renewed patent exposure on both Jakafi® (ruxolitinib) and Olumiant® (baricitinib) under US9662335B2. The precise commercial impact depends on what occurs in any remand proceedings, including how claim scope is ultimately determined by the lower tribunal.
The appeal ran 176 days from filing (12 November 2024) to decision (7 May 2025). This is notably swift for a pharmaceutical patent appeal at the Federal Circuit and is consistent with the panel having resolved a discrete threshold legal question — such as claim construction, standing, or patent eligibility — rather than conducting a full merits re-examination of complex factual findings.
CTP-543, also known as deuruxolitinib, is a deuterated JAK inhibitor developed by Sun Pharmaceutical targeting alopecia areata. Its inclusion among the products at issue in this appeal indicates that the claim scope of US9662335B2 was argued to encompass deuterated variants of the ruxolitinib scaffold, making the Federal Circuit’s reversal directly relevant to Sun’s freedom to develop and commercialise this pipeline asset.
PatSnap Eureka searches patents and litigation data to answer instantly.